EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis

Zi-Han Zhang, Si-Nan Hou, Jia-Ze Yu, Wen Zhang, Jing-Qin Ma, Min-Jie Yang, Qing-Xin Liu, Ling-Xiao Liu, Jian-Jun Luo, Xu-Dong Qu, Zhi-Ping Yan

Frontiers in Oncology · 19.01.2023 · 12

DOI: 10.3389/fonc.2022.1086095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.01.2023. Verfasst von Zi-Han Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety and efficacy of interventional therapy (iodine-125[ 125 I] seed strand and portal vein stent [PVS] implantation plus transarterial chemoembolization [TACE]) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) as first-line treatment for hepatocellular carcinoma (HCC) patients with Vp4 portal vein tumor thrombus (PVTT). Patients and methods From December 2018 to October 2021, 87 HCC patients with Vp4 PVTT were included in this single-center retrospective study. Forty-seven patients underwent interventional therapy combined with lenvatinib and anti-PD-1 antibody (group A), while 40 cases underwent interventional therapy combined with lenvatinib only (group B). Overall response rate (ORR), stent occlusion rates (SOR), median overall survival (OS), median progression-free survival (PFS) and median stent patency time (SPT) were compared between the 2 groups.

Results

The mean intended dose (r = 10 mm; z = 0; 240 days) was 64.9 ± 1.0 Gy and 64.5 ± 1.1 Gy in group A and B, respectively ( p = 0.133). ORR and SOR were significantly different between group A and B (ORR, 55.3% vs 17.5%, p < 0.001; SOR, 12.8% vs 35.0%, p = 0.014). In the propensity-score matching (PSM) cohort, the median OS, median PFS and median SPT were significantly longer in group A compared with group B (32 PSM pairs; OS, 17.7 ± 1.7 vs 12.0 ± 0.8 months, p = 0.010; PFS, 17.0 ± 4.3 vs 8.0 ± 0.7 months, p < 0.001; SPT, not-reached vs 12.5 ± 1.1 months, p = 0.028).

Conclusion

This interventional therapy combined with lenvatinib and anti-PD-1 antibody is safe and effective for HCC patients with Vp4 PVTT.

Schlagwörter

Stichwörter der Autor:innen

anti-PD-1 antibodyhepatocellular carcinomaiodine-125 seed strandlenvatinibportal vein tumor thrombustransarterial chemoembolization

Autor:innen und Institutionen

  • Department of Interveintional Radiology, Zhongshan hospital, Fudan, University, Shanghai, China.
  • Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China.
  • National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Zitieren

APA

Zhang, Z. H., Hou, S. N., Yu, J. Z., Zhang, W., Ma, J. Q., Yang, M. J., Liu, Q. X., Liu, L. X., Luo, J. J., Qu, X. D., & Yan, Z. P. (2023). Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1086095

Vancouver

Zhang ZH, Hou SN, Yu JZ, Zhang W, Ma JQ, Yang MJ, et al. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1086095

BibTeX
@article{Zhang2023,
  author = {Zhang, Zi-Han and Hou, Si-Nan and Yu, Jia-Ze and Zhang, Wen and Ma, Jing-Qin and Yang, Min-Jie and Liu, Qing-Xin and Liu, Ling-Xiao and Luo, Jian-Jun and Qu, Xu-Dong and Yan, Zhi-Ping},
  title = {Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {12},
  doi = {10.3389/fonc.2022.1086095}
}
Kostenlos starten →